MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
2.600
+0.030 (1.17%)
Apr 8, 2026, 2:28 PM EDT - Market open
MannKind Employees
As of December 31, 2025, MannKind had 592 total employees, including 591 full-time and 1 part-time employees. The number of employees increased by 185 or 45.45% compared to the previous year.
Employees
592
Change (1Y)
185
Growth (1Y)
45.45%
Revenue / Employee
$589,470
Profits / Employee
$9,904
Market Cap
801.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 592 | 185 | 45.45% | 591 | 1 |
| Dec 31, 2024 | 407 | -7 | -1.69% | 403 | 4 |
| Dec 31, 2023 | 414 | 19 | 4.81% | 411 | 3 |
| Dec 31, 2022 | 395 | 46 | 13.18% | 391 | 4 |
| Dec 31, 2021 | 349 | 108 | 44.81% | 348 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Maravai LifeSciences Holdings | 435 |
| MeiraGTx Holdings | 403 |
| Kura Oncology | 260 |
| Omeros | 175 |
| Solid Biosciences | 121 |
| Theravance Biopharma | 90 |
| Jade Biosciences | 55 |
| Design Therapeutics | 54 |
MNKD News
- 4 weeks ago - MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 - GlobeNewsWire
- 4 weeks ago - MannKind Announces Settlement of Convertible Senior Notes - GlobeNewsWire
- 5 weeks ago - MannKind to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 7 weeks ago - MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire
- 2 months ago - MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D) - GlobeNewsWire
- 2 months ago - MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy - GlobeNewsWire